Neogen Corporation has displayed steady revenue growth over recent years but suffers from significant operating losses, culminating in a net loss exceeding $1 billion in fiscal 2025 [F1]. The company’s robust liquidity position, as shown by a current ratio near 4.0 and cash ratio above 1.0 as of February 2026 [S2], provides operational stability amid ongoing restructuring, including the $160 million sale of its genomics unit to Zoetis [N1]. Newly appointed CFO Bryan Riggsbee brings extensive bio-industry finance experience, potentially guiding more disciplined capital allocation and cost management. Market watchers will observe upcoming quarterly earnings and margin improvement initiatives for signals on whether Neogen can convert its revenue momentum into sustainable profitability.